{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"ATS Assemblies & Sections","title":"Tirzepatide SURMOUNT-OSA trial and cardiometabolic subanalysis","html":"","width":"100%","height":180,"duration":1609,"description":"April 21, 2026\nA Podcast on Tirzepatide SURMOUNT-OSA trial and cardiometabolic subanalysis.\nA portion of the ATS SRN 360 high impact articles from the past year.\n• Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity – Presented by Richard J Schwab, MD - Perelman School of Medicine, University of Pennsylvania, Philadelphia; the Division of Sleep and Circadian Disorders\n• Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.\nPresented by Scott A. Sands, Ph.D - Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts\nModerated by Chana Chin, MD from CHOC Children's/Rady's Children's Health and Bradon Nokes, MD from University of California, San Diego\n00:00 — Podcast Introduction & Presentation Overview 00:15 — Tirzepatide for Obstructive Sleep Apnea and Obesity 00:47 — SURMOUNT-OSA Trial Design and Patient Population 01:44 — Primary Endpoints and Secondary Outcome Measures 02:53 — Baseline Demographics and Clinical Characteristics 03:52 — Weight Loss Effects and Sleep Apnea Improvement Results 05:52 — Cardiometabolic Outcomes, Blood Pressure, and Safety Findings 08:40 — Clinical Discussion: Prescribing Tirzepatide in OSA Practice 12:03 — Secondary Analysis of Cardiometabolic Risk Mediation 20:08 — Long-Term Use, Mechanisms of Action, and Audience Q&A","thumbnail_url":"https://img.transistorcdn.com/9DaPUiuZAWF4aqHRUVM8yVGNq8O1aIe3EajK-tlwSGU/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS83OTVl/MDQ0ZDc5MGUwMThk/NDZkZjBhNWNmZTNm/NGZmOC5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}